PEAR-TNBC
Early-stage triple negative breast cancer (neoadjuvant setting)
Key Facts
About Pear Bio
Pear Bio is a private, pre-revenue biotech developing a functional precision oncology platform that bridges diagnostics and drug discovery. Its core technology involves generating 3D immune-microtumors from patient biopsies to empirically test multiple therapies in parallel, aiming to predict clinical response and match patients with effective treatments. The company is currently running observational clinical trials in triple-negative breast cancer (TNBC) to validate its predictive assay while simultaneously using its platform for novel target identification. Pear Bio operates at the intersection of personalized testing services and therapeutic development, targeting a significant unmet need in oncology.
View full company profile